Assessing the risk of osteonecrosis of the jaw due to bisphosphonate therapy in the secondary prevention of osteoporotic fractures
Osteoporosis International, 06/13/2012
Lapi F et al. – Although the risk of bisphosphonate (BP)–related osteronecrosis of the jaws (ONJ) appears low in non–oncological indications, it is important to be aware that it exists and to know how it may be predicted and possibly minimized.



